drugset / Trial / NCT07378306
FMD and Neoadjuvant Chemo-immunotherapy in TNBC
NaSingle-groupOpen-labelTreatment
Summary
The primary objective of this study is to investigate the efficacy and safety of a fasting-mimicking diet (FMD) intervention combined with standard neoadjuvant chemoimmunotherapy in early-stage or locally advanced triple-negative breast cancer (TNBC).
Timeline
- Start
- 2026-03-05
- Primary completion
- 2029-06-30
- Completion
- 2029-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Background | Cyclophosphamide | Other / unclassified | — | — |
| Background | Docetaxel | Small molecule | — | — |
| Background | Doxorubicin | Other / unclassified | — | — |
| Background | Epirubicin | Small molecule | — | — |
| Background | Nab-paclitaxel | Small molecule | — | — |
| Background | Paclitaxel | Small molecule | — | — |
| Background | Pirarubicin | Small molecule | — | — |
| Background | Toripalimab | Monoclonal antibody | 240 mg | Intravenous |